These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2007929)

  • 21. Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome-Reply.
    Dargaville PA; Carlin JB; Davis PG;
    JAMA; 2022 Apr; 327(16):1614-1615. PubMed ID: 35471518
    [No Abstract]   [Full Text] [Related]  

  • 22. Hot topics in and new strategies for surfactant research.
    Jobe AH
    Biol Neonate; 1998 Sep; 74 Suppl 1():3-8. PubMed ID: 9730585
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathology of neonatal surfactant deficiency.
    Robertson B
    Perspect Pediatr Pathol; 1987; 11():6-46. PubMed ID: 3110733
    [No Abstract]   [Full Text] [Related]  

  • 24. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of surfactant in the prevention and treatment of neonatal respiratory distress syndrome.
    Reynolds MS; Wallander KA
    Clin Pharm; 1989 Aug; 8(8):559-76. PubMed ID: 2670398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
    Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
    Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 grams.
    Ferrara TB; Hoekstra RE; Couser RJ; Jackson JC; Anderson CL; Myers TF; Raye JR
    J Pediatr; 1991 Sep; 119(3):455-7. PubMed ID: 1880661
    [No Abstract]   [Full Text] [Related]  

  • 29. Surfactant replacement therapy.
    Yee WF; Scarpelli EM
    Pediatr Pulmonol; 1991; 11(1):65-80. PubMed ID: 1923669
    [No Abstract]   [Full Text] [Related]  

  • 30. Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.
    Merritt TA; Hallman M; Spragg R; Heldt GP; Gilliard N
    Drugs; 1989 Oct; 38(4):591-611. PubMed ID: 2684594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perinatal prevention of bronchopulmonary dysplasia.
    Greenough A; Ahmed N
    J Perinat Med; 2013 Jan; 41(1):119-26. PubMed ID: 23096098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal derived surfactant extract for treatment of respiratory distress syndrome.
    Seger N; Soll R
    Cochrane Database Syst Rev; 2009 Apr; (2):CD007836. PubMed ID: 19370695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia.
    Verder H; Bohlin K; Kamper J; Lindwall R; Jonsson B
    Acta Paediatr; 2009 Sep; 98(9):1400-8. PubMed ID: 19572989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Surfactant treatment of premature infants with respiratory distress syndrome].
    Saugstad OD; Gloppestad K
    Tidsskr Nor Laegeforen; 1990 Nov; 110(29):3737-41. PubMed ID: 2274941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surfactant replacement therapy for neonatal respiratory distress syndrome.
    Dhanireddy R
    Indian J Pediatr; 1990; 57(6):743-9. PubMed ID: 2131303
    [No Abstract]   [Full Text] [Related]  

  • 37. Club cell protein expression amongst infants with respiratory distress syndrome.
    Rallis D; Baltogianni M; Dermitzaki N; Balomenou F; Papastergiou E; Maragoudaki E; Tsabouri S; Makis A; Giapros V
    Pediatr Pulmonol; 2022 Jun; 57(6):1543-1546. PubMed ID: 35304828
    [No Abstract]   [Full Text] [Related]  

  • 38. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
    Ardell S; Pfister RH; Soll R
    Cochrane Database Syst Rev; 2015 May; (5):CD000144. PubMed ID: 26009996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
    Yost CC; Soll RF
    Cochrane Database Syst Rev; 2000; (2):CD001456. PubMed ID: 10796266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nasopharyngeal surfactant administration to prevent neonatal respiratory distress syndrome.
    Fernandes CJ; Horst DA; O'Donovan DJ
    J Perinatol; 2005 May; 25(5):361-2; author reply 363. PubMed ID: 15861205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.